{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T07:33:15Z","timestamp":1781163195066,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,6,10]],"date-time":"2015-06-10T00:00:00Z","timestamp":1433894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,6,10]],"date-time":"2015-06-10T00:00:00Z","timestamp":1433894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>We have previously identified endogenously citrullinated peptides derived from fibrinogen in rheumatoid arthritis (RA) synovial tissues. In this study, we have investigated the auto-antigenicity of four of those citrullinated peptides, and explored their feasibility to target anti-citrullinated protein\/peptide antibodies (ACPA).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>The autoantigenic potential of the fibrinogen peptides was investigated by screening 927 serum samples from the Epidemiological Investigation of RA (EIRA) cohort on a peptide microarray based on the ImmunoCAP ISAC\u00ae system. In order to assay for ACPA blocking, two independent pools of purified ACPA were incubated with the respective targeting peptide prior to binding to cyclic citrullinated peptide (CCP)2 using the CCPlus\u00ae ELISA kit.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Two peptides derived from the fibrinogen \u03b1 chain, Arg573Cit (563-583) and Arg591Cit (580-600), referred to as Cit573 and Cit591, and two peptides from the fibrinogen \u03b2 chain, Arg72Cit (62-81) and Arg74Cit (62-81) (Cit72 and Cit74), displayed 65 %, 15 %, 35 %, and 53 % of immune reactivity among CCP2-positive RA sera, respectively. In CCP2-negative RA sera, a positive reactivity was detected in 5 % (Cit573), 6 % (Cit591), 8 % (Cit72), and 4 % (Cit74). In the competition assay, Cit573 and Cit591 peptides reduced ACPA binding to CCP2 by a maximum of 84 % and 63 % respectively. An additive effect was observed when these peptides were combined. In contrast, Cit74 and Cit72 were less effective. Cyclization of the peptide structure containing Cit573 significantly increased the blocking efficiency.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>Here we demonstrate extensive autoantibody reactivity against <jats:italic>in vivo<\/jats:italic> citrullinated fibrinogen epitopes, and further show the potential use of these peptides for antagonizing ACPA.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/s13075-015-0666-6","type":"journal-article","created":{"date-parts":[[2015,6,10]],"date-time":"2015-06-10T15:53:08Z","timestamp":1433951588000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Targeting of anti-citrullinated protein\/peptide antibodies in rheumatoid arthritis using peptides mimicking endogenously citrullinated fibrinogen antigens"],"prefix":"10.1186","volume":"17","author":[{"given":"C\u00e1tia","family":"Fernandes-Cerqueira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ossipova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunithi","family":"Gunasekera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Mathsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca I.","family":"Catrina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yngve","family":"Sommarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Klareskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"R\u00f6nnelid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"G\u00f6ransson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per-Johan","family":"Jakobsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,10]]},"reference":[{"key":"666_CR1","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1136\/ard.2006.051391","volume":"65","author":"J Avouac","year":"2006","unstructured":"Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2006;65:845\u201351.","journal-title":"Ann Rheum Dis."},{"key":"666_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3","volume":"43","author":"GA Schellekens","year":"2000","unstructured":"Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000;43:155\u201363.","journal-title":"Arthritis Rheum."},{"key":"666_CR3","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.4049\/jimmunol.166.6.4177","volume":"166","author":"C Masson-Bessiere","year":"2001","unstructured":"Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol. 2001;166:4177\u201384.","journal-title":"J Immunol."},{"key":"666_CR4","doi-asserted-by":"publisher","first-page":"R1421","DOI":"10.1186\/ar1845","volume":"7","author":"A Kinloch","year":"2005","unstructured":"Kinloch A, Tatzer V, Wait R, Peston D, Lundberg K, Donatien P, et al. Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther. 2005;7:R1421\u20139.","journal-title":"Arthritis Res Ther."},{"key":"666_CR5","doi-asserted-by":"publisher","first-page":"R142","DOI":"10.1186\/ar1149","volume":"6","author":"ER Vossenaar","year":"2004","unstructured":"Vossenaar ER, Despres N, Lapointe E, van der Heijden A, Lora M, Senshu T, et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther. 2004;6:R142\u201350.","journal-title":"Arthritis Res Ther."},{"key":"666_CR6","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1002\/eji.200526000","volume":"35","author":"H Burkhardt","year":"2005","unstructured":"Burkhardt H, Sehnert B, Bockermann R, Engstrom A, Kalden JR, Holmdahl R. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur J Immunol. 2005;35:1643\u201352.","journal-title":"Eur J Immunol."},{"key":"666_CR7","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1002\/art.11223","volume":"48","author":"S Rantapaa-Dahlqvist","year":"2003","unstructured":"Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48:2741\u20139.","journal-title":"Arthritis Rheum."},{"key":"666_CR8","doi-asserted-by":"publisher","first-page":"R949","DOI":"10.1186\/ar1767","volume":"7","author":"AH van der Helm-van Mil","year":"2005","unstructured":"van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther. 2005;7:R949\u201358.","journal-title":"Arthritis Res Ther."},{"key":"666_CR9","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1172\/JCI25422","volume":"116","author":"KA Kuhn","year":"2006","unstructured":"Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson WH, et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest. 2006;116:961\u201373.","journal-title":"J Clin Invest."},{"key":"666_CR10","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/art.23284","volume":"58","author":"C Clavel","year":"2008","unstructured":"Clavel C, Nogueira L, Laurent L, Iobagiu C, Vincent C, Sebbag M, et al. Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum. 2008;58:678\u201388.","journal-title":"Arthritis Rheum."},{"key":"666_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/art.30081","volume":"63","author":"J Sokolove","year":"2011","unstructured":"Sokolove J, Zhao X, Chandra PE, Robinson WH. Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcgamma receptor. Arthritis Rheum. 2011;63:53\u201362.","journal-title":"Arthritis Rheum."},{"key":"666_CR12","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1002\/art.24622","volume":"60","author":"LA Trouw","year":"2009","unstructured":"Trouw LA, Haisma EM, Levarht EW, van der Woude D, Ioan-Facsinay A, Daha MR, et al. Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum. 2009;60:1923\u201331.","journal-title":"Arthritis Rheum."},{"key":"666_CR13","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1172\/JCI60975","volume":"122","author":"U Harre","year":"2012","unstructured":"Harre U, Georgess D, Bang H. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest. 2012;122:1791\u2013802.","journal-title":"J Clin Invest."},{"key":"666_CR14","doi-asserted-by":"publisher","first-page":"178ra140","DOI":"10.1126\/scitranslmed.3005580","volume":"5","author":"R Khandpur","year":"2013","unstructured":"Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, Gizinski A, Yalavarthi S, Knight JS, et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med. 2013;5:178ra140.","journal-title":"Sci Transl Med"},{"key":"666_CR15","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1055\/s-0030-1251506","volume":"36","author":"R Jahns","year":"2010","unstructured":"Jahns R, Schlipp A, Boivin V, Lohse MJ. Targeting receptor antibodies in immune cardiomyopathy. Semin Thromb Hemost. 2010;36:212\u20138.","journal-title":"Semin Thromb Hemost."},{"key":"666_CR16","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/eurjhf\/hfs118","volume":"14","author":"G Munch","year":"2012","unstructured":"Munch G, Boivin-Jahns V, Holthoff HP, Adler K, Lappo M, Truol S, et al. Administration of the cyclic peptide COR-1 in humans (phase I study): ex vivo measurements of anti-beta1-adrenergic receptor antibody neutralization and of immune parameters. Eur J Heart Fail. 2012;14:1230\u20139.","journal-title":"Eur J Heart Fail."},{"key":"666_CR17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/prca.200900088","volume":"4","author":"M Hermansson","year":"2010","unstructured":"Hermansson M, Artemenko K, Ossipova E, Eriksson H, Lengqvist J, Makrygiannakis D, et al. MS analysis of rheumatoid arthritic synovial tissue identifies specific citrullination sites on fibrinogen. Proteomics Clin Appl. 2010;4:511\u20138.","journal-title":"Proteomics Clin Appl."},{"key":"666_CR18","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1002\/eji.200535790","volume":"36","author":"M Sebbag","year":"2006","unstructured":"Sebbag M, Moinard N, Auger I, Clavel C, Arnaud J, Nogueira L, et al. Epitopes of human fibrin recognized by the rheumatoid arthritis-specific autoantibodies to citrullinated proteins. Eur J Immunol. 2006;36:2250\u201363.","journal-title":"Eur J Immunol."},{"key":"666_CR19","doi-asserted-by":"publisher","first-page":"R94","DOI":"10.1186\/ar2478","volume":"10","author":"X Zhao","year":"2008","unstructured":"Zhao X, Okeke NL, Sharpe O, Batliwalla FM, Lee AT, Ho PP, et al. Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res Ther. 2008;10:R94.","journal-title":"Arthritis Res Ther."},{"key":"666_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315\u201324.","journal-title":"Arthritis Rheum."},{"key":"666_CR21","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1126\/science.7973629","volume":"266","author":"PE Dawson","year":"1994","unstructured":"Dawson PE, Muir TW, Clark-Lewis I, Kent SB. Synthesis of proteins by native chemical ligation. Science. 1994;266:776\u20139.","journal-title":"Science."},{"key":"666_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10989-012-9331-y","volume":"19","author":"S Gunasekera","year":"2013","unstructured":"Gunasekera S, Aboye TL, Madian WA, El-Seedi HR, Goransson U. Making ends meet: microwave-accelerated synthesis of cyclic and disulfide rich proteins via in situ thioesterification and native chemical ligation. Int J Pept Res Ther. 2013;19:43\u201354.","journal-title":"Int J Pept Res Ther."},{"key":"666_CR23","doi-asserted-by":"publisher","first-page":"R201","DOI":"10.1186\/ar4039","volume":"14","author":"M Hansson","year":"2012","unstructured":"Hansson M, Mathsson L, Schlederer T, Israelsson L, Matsson P, Nogueira L, et al. Validation of a multiplex chip-based assay for the detection of autoantibodies against citrullinated peptides. Arthritis Res Ther. 2012;14:R201.","journal-title":"Arthritis Res Ther."},{"key":"666_CR24","doi-asserted-by":"publisher","first-page":"R167","DOI":"10.1186\/ar4683","volume":"16","author":"E Ossipova","year":"2014","unstructured":"Ossipova E, Cerqueira CF, Reed E, Kharlamova N, Israelsson L, Holmdahl R, et al. Affinity purified anti-citrullinated protein\/peptide antibodies target antigens expressed in the rheumatoid joint. Arthritis Res Ther. 2014;16:R167.","journal-title":"Arthritis Res Ther."},{"key":"666_CR25","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1124\/pr.55.4.4","volume":"55","author":"RR Neubig","year":"2003","unstructured":"Neubig RR, Spedding M, Kenakin T, Christopoulos A, International Union of Pharmacology Committee on Receptor N, Drug C. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev. 2003;55:597\u2013606.","journal-title":"Pharmacol Rev"},{"key":"666_CR26","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1136\/annrheumdis-2012-201484","volume":"72","author":"K Lundberg","year":"2013","unstructured":"Lundberg K, Bengtsson C, Kharlamova N, Reed E, Jiang X, Kallberg H, et al. Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein\/peptide antibody fine specificity profile. Ann Rheum Dis. 2013;72:652\u20138.","journal-title":"Ann Rheum Dis."},{"key":"666_CR27","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1136\/annrheumdis-2013-203915","volume":"74","author":"CA Wagner","year":"2014","unstructured":"Wagner CA, Sokolove J, Lahey LJ, Bengtsson C, Saevarsdottir S, Alfredsson L, et al. Identification of anticitrullinated protein antibody reactivities in a subset of anti-CCP-negative rheumatoid arthritis: association with cigarette smoking and HLA-DRB1 \u2018shared epitope\u2019 alleles. Ann Rheum Dis. 2014;74:579\u20138.","journal-title":"Ann Rheum Dis."},{"key":"666_CR28","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/art.37835","volume":"65","author":"M Brink","year":"2013","unstructured":"Brink M, Hansson M, Mathsson L, Jakobsson PJ, Holmdahl R, Hallmans G, et al. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum. 2013;65:899\u2013910.","journal-title":"Arthritis Rheum."},{"key":"666_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/bcpt.12157","volume":"114","author":"CF Cerqueira","year":"2014","unstructured":"Cerqueira CF, Klareskog L, Jakobsson PJ. Neutralization of anticitrullinated protein antibodies in rheumatoid arthritis - a way to go? Basic Clin Pharmacol Toxicol. 2014;114:13\u20137.","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"666_CR30","doi-asserted-by":"publisher","first-page":"658","DOI":"10.4049\/jimmunol.1301904","volume":"192","author":"AM Farkas","year":"2014","unstructured":"Farkas AM, Finn OJ. Novel mechanisms underlying the immediate and transient global tolerization of splenic dendritic cells after vaccination with a self-antigen. J Immunol. 2014;192:658\u201365.","journal-title":"J Immunol."},{"key":"666_CR31","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.4049\/jimmunol.1203321","volume":"190","author":"AM Farkas","year":"2013","unstructured":"Farkas AM, Marvel DM, Finn OJ. Antigen choice determines vaccine-induced generation of immunogenic versus tolerogenic dendritic cells that are marked by differential expression of pancreatic enzymes. J Immunol. 2013;190:3319\u201327.","journal-title":"J Immunol."},{"key":"666_CR32","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.4049\/jimmunol.162.10.5775","volume":"162","author":"A Kaliyaperumal","year":"1999","unstructured":"Kaliyaperumal A, Michaels MA, Datta SK. Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells. J Immunol. 1999;162:5775\u201383.","journal-title":"J Immunol."},{"key":"666_CR33","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.4049\/jimmunol.174.6.3247","volume":"174","author":"HK Kang","year":"2005","unstructured":"Kang HK, Michaels MA, Berner BR, Datta SK. Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J Immunol. 2005;174:3247\u201355.","journal-title":"J Immunol."},{"key":"666_CR34","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.4049\/jimmunol.169.2.1126","volume":"169","author":"HY Wu","year":"2002","unstructured":"Wu HY, Ward FJ, Staines NA. Histone peptide-induced nasal tolerance: suppression of murine lupus. J Immunol. 2002;169:1126\u201334.","journal-title":"J Immunol."},{"key":"666_CR35","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/intimm\/7.4.689","volume":"7","author":"A Waisman","year":"1995","unstructured":"Waisman A, Shoenfeld Y, Blank M, Ruiz PJ, Mozes E. The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 gene segment. Int Immunol. 1995;7:689\u201396.","journal-title":"Int Immunol."},{"key":"666_CR36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3109\/08916930109007385","volume":"34","author":"AL Caforio","year":"2001","unstructured":"Caforio AL, Mahon NJ, McKenna WJ. Cardiac autoantibodies to myosin and other heart-specific autoantigens in myocarditis and dilated cardiomyopathy. Autoimmunity. 2001;34:199\u2013204.","journal-title":"Autoimmunity."},{"key":"666_CR37","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1161\/CIRCRESAHA.111.253849","volume":"109","author":"A Haberland","year":"2011","unstructured":"Haberland A, Wallukat G, Dahmen C, Kage A, Schimke I. Aptamer neutralization of beta1-adrenoceptor autoantibodies isolated from patients with cardiomyopathies. Circ Res. 2011;109:986\u201392.","journal-title":"Circ Res."},{"key":"666_CR38","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4049\/jimmunol.126.1.16","volume":"126","author":"L Pearson","year":"1981","unstructured":"Pearson L, Lightfoot Jr RW. Correlation of DNA-anti-DNA association rates with clinical activity in systemic lupus erythematosus (SLE). J Immunol. 1981;126:16\u20139.","journal-title":"J Immunol."},{"key":"666_CR39","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1073\/pnas.94.5.1955","volume":"94","author":"B Gaynor","year":"1997","unstructured":"Gaynor B, Putterman C, Valadon P, Spatz L, Scharff MD, Diamond B. Peptide inhibition of glomerular deposition of an anti-DNA antibody. Proc Natl Acad Sci U S A. 1997;94:1955\u201360.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"666_CR40","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1365-2796.2010.02318.x","volume":"269","author":"B Diamond","year":"2011","unstructured":"Diamond B, Bloom O, Al Abed Y, Kowal C, Huerta PT, Volpe BT. Moving towards a cure: blocking pathogenic antibodies in systemic lupus erythematosus. J Intern Med. 2011;269:36\u201344.","journal-title":"J Intern Med."},{"key":"666_CR41","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1136\/ard.2010.148759","volume":"70","author":"K Chatzidionysiou","year":"2011","unstructured":"Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis. 2011;70:1575\u201380.","journal-title":"Ann Rheum Dis."},{"key":"666_CR42","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2011-201117","volume":"72","author":"JD Isaacs","year":"2013","unstructured":"Isaacs JD, Cohen SB, Emery P, Tak PP, Wang J, Lei G, et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis. 2013;72:329\u201336.","journal-title":"Ann Rheum Dis."},{"key":"666_CR43","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jbspin.2014.06.001","volume":"81","author":"A Gardette","year":"2014","unstructured":"Gardette A, Ottaviani S, Tubach F, Roy C, Nicaise-Roland P, Palazzo E, et al. High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis. Joint Bone Spine. 2014;81:416\u201320.","journal-title":"Joint Bone Spine."},{"key":"666_CR44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2013.12.002","volume":"50","author":"G Cambridge","year":"2014","unstructured":"Cambridge G, Perry HC, Nogueira L, Serre G, Parsons HM, De La Torre I, et al. The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment. J Autoimmun. 2014;50:67\u201376.","journal-title":"J Autoimmun."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0666-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-015-0666-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0666-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0666-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:04:59Z","timestamp":1728921899000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-015-0666-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,10]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12]]}},"alternative-id":["666"],"URL":"https:\/\/doi.org\/10.1186\/s13075-015-0666-6","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,10]]},"assertion":[{"value":"17 January 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"155"}}